About The Study: Muvalaplin was not associated with tolerability concerns and lowered lipoprotein(a) (Lp[a]) levels up to 65% following daily administration for 14 days in this first-in-human phase 1 study involving healthy participants. Lipoprotein(a) is associated with atherosclerotic disease and aortic stenosis. Longer and larger trials will be required to further evaluate safety, tolerability, and effect of muvalaplin on Lp(a) levels and cardiovascular outcomes.
Authors: Stephen J. Nicholls, M.B.B.S., Ph.D., of Monash University in Clayton, Victoria, Australia, is the corresponding author.
To access the embargoed study: Visit our For The Media website at this link https://media.jamanetwork.com/
(doi:10.1001/jama.2023.16503)
Editor’s Note: Please see the article for additional information, including other authors, author contributions and affiliations, conflict of interest and financial disclosures, and funding and support.
# # #
Media advisory: This study is being released to coincide with presentation at the European Society of Cardiology Congress 2023.
Embed this link to provide your readers free access to the full-text article This link will be live at the embargo time https://jamanetwork.com/journals/jama/fullarticle/10.1001/jama.2023.16503?guestAccessKey=d859c2e4-3c05-4b02-8fca-a109964432bd&utm_source=For_The_Media&utm_medium=referral&utm_campaign=ftm_links&utm_content=tfl&utm_term=082823
Journal
JAMA